Cytek Biosciences Net Worth
Cytek Biosciences Net Worth Breakdown | CTKB |
Cytek Biosciences Net Worth Analysis
Cytek Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cytek Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cytek Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cytek Biosciences' net worth analysis. One common approach is to calculate Cytek Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cytek Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cytek Biosciences' net worth. This approach calculates the present value of Cytek Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cytek Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cytek Biosciences' net worth. This involves comparing Cytek Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cytek Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Cytek Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cytek Biosciences' net worth research are outlined below:
| Cytek Biosciences generated a negative expected return over the last 90 days | |
| Cytek Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 111.11 M. | |
| About 61.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Cytek Biosciences Overweight Rating Reaffirmed at Stephens |
Cytek Biosciences Quarterly Good Will |
|
Cytek Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cytek Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cytek Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cytek Biosciences Target Price Consensus
Cytek target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cytek Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Buy |
Most Cytek analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cytek stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cytek Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCytek Biosciences Target Price Projection
Cytek Biosciences' current and average target prices are 4.06 and 8.40, respectively. The current price of Cytek Biosciences is the price at which Cytek Biosciences is currently trading. On the other hand, Cytek Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cytek Biosciences Market Quote on 20th of March 2025
Target Price
Analyst Consensus On Cytek Biosciences Target Price
Know Cytek Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cytek Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cytek Biosciences backward and forwards among themselves. Cytek Biosciences' institutional investor refers to the entity that pools money to purchase Cytek Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.1 M | Jpmorgan Chase & Co | 2024-12-31 | 947.7 K | Millennium Management Llc | 2024-12-31 | 803.9 K | Bank Of New York Mellon Corp | 2024-12-31 | 730.7 K | Fmr Inc | 2024-12-31 | 683.2 K | Ubs Group Ag | 2024-12-31 | 665.7 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 601.7 K | Principal Financial Group Inc | 2024-12-31 | 506.9 K | Blackrock Inc | 2024-12-31 | 18.5 M | Vanguard Group Inc | 2024-12-31 | 11.7 M |
Follow Cytek Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 540.57 M.Market Cap |
|
Project Cytek Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.02) | (0.02) |
When accessing Cytek Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cytek Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cytek Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Cytek Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytek Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cytek Biosciences' management manipulating its earnings.
Evaluate Cytek Biosciences' management efficiency
Cytek Biosciences has return on total asset (ROA) of (0.0291) % which means that it has lost $0.0291 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0153) %, meaning that it created substantial loss on money invested by shareholders. Cytek Biosciences' management efficiency ratios could be used to measure how well Cytek Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 20, 2025, Return On Tangible Assets is expected to decline to -0.01. The current year's Return On Capital Employed is expected to grow to -0.05. At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5 M, whereas Total Assets are forecasted to decline to about 415.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.02 | 1.56 | |
| Tangible Book Value Per Share | 2.74 | 1.46 | |
| Enterprise Value Over EBITDA | (36.99) | (35.14) | |
| Price Book Value Ratio | 2.15 | 2.26 | |
| Enterprise Value Multiple | (36.99) | (35.14) | |
| Price Fair Value | 2.15 | 2.26 | |
| Enterprise Value | 759.1 M | 721.1 M |
Understanding the management dynamics of Cytek Biosciences allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Enterprise Value Revenue 1.3955 | Revenue | Quarterly Revenue Growth (0.01) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytek Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytek Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytek Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cytek Biosciences Corporate Filings
F4 | 12th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 28th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Cytek Biosciences Earnings Estimation Breakdown
The calculation of Cytek Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Cytek Biosciences is estimated to be -0.04 with the future projection ranging from a low of 0.01 to a high of 0.01. Please be aware that this consensus of annual earnings estimates for Cytek Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.01 Lowest | Expected EPS | 0.01 Highest |
Cytek Biosciences Earnings Projection Consensus
Suppose the current estimates of Cytek Biosciences' value are higher than the current market price of the Cytek Biosciences stock. In this case, investors may conclude that Cytek Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cytek Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 6 | 21.1% | 0.1155 | -0.04 | -0.05 |
Cytek Biosciences Earnings History
Earnings estimate consensus by Cytek Biosciences analysts from Wall Street is used by the market to judge Cytek Biosciences' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Cytek Biosciences' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Cytek Biosciences Quarterly Gross Profit |
|
Cytek Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Cytek Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cytek Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Cytek Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Cytek Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Cytek Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cytek Biosciences should always be considered in relation to other companies to make a more educated investment decision.Cytek Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Cytek Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-28 | 2024-12-31 | 0.1033 | 0.1155 | 0.0122 | 11 | ||
2024-11-06 | 2024-09-30 | 0.0367 | 0.0558 | 0.0191 | 52 | ||
2024-08-06 | 2024-06-30 | -0.03 | -0.08 | -0.05 | 166 | ||
2024-05-08 | 2024-03-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2024-02-28 | 2023-12-31 | 0.01 | 0.04 | 0.03 | 300 | ||
2023-11-07 | 2023-09-30 | 0.03 | -0.05 | -0.08 | 266 | ||
2023-08-08 | 2023-06-30 | 0.03 | -0.03 | -0.06 | 200 | ||
2023-05-09 | 2023-03-31 | 0.03 | -0.05 | -0.08 | 266 | ||
2023-02-28 | 2022-12-31 | 0.05 | 0.06 | 0.01 | 20 | ||
2022-11-09 | 2022-09-30 | 0.02 | 0.04 | 0.02 | 100 | ||
2022-08-10 | 2022-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2022-05-11 | 2022-03-31 | -0.01 | 0.01 | 0.02 | 200 | ||
2022-02-23 | 2021-12-31 | 0.03 | 0.03 | 0.0 | 0 | ||
2021-11-08 | 2021-09-30 | 0.02 | 0.02 | 0.0 | 0 | ||
2021-09-03 | 2021-06-30 | 0.02 | 0.07 | 0.05 | 250 | ||
null | null | null | null | null | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.03 | -0.03 | 0 |
Cytek Biosciences Corporate Management
| Todd Garland | Chief Officer | Profile | |
| Ming Yan | CTO Director | Profile | |
| Melik Ulusu | Senior Chain | Profile | |
| Mark Edinger | VP Affairs | Profile | |
| Allen Poirson | Senior Development | Profile | |
| Connie Wedel | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.735 | Earnings Share (0.05) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.